Advertisement

In clinical trials, the new drug, BG-12, has been shown to lower the number of nerve cell attacks with fewer side effects. It is expected to cost about $50,000 per year, the same as similar drugs.

 

Visit NBCNews.com for breaking news, world news, and news about the economy

Advertisement
Advertisement